Robust gelatin hydrogels for local sustained release of bupivacaine following spinal surgery
Source abstract
Abstract
Adequate treatment of pain arising from spinal surgery is a major clinical challenge. Opioids are the mainstay of current treatment methods, but the frequency and severity of their side effects display a clear need for opioid-free analgesia. Local anesthetics have been encapsulated into sustained-release drug delivery systems to provide postoperative pain relief. However, these formulations are limited by rapid diffusion out of the surgical site. To overcome this limitation, we synthesized ring-shaped hydrogels incorporating bupivacaine, designed to be co-implanted with pedicle screws during spinal surgery. Hydrogels were prepared by riboflavin-mediated crosslinking of gelatin functionalized with tyramine moieties. Additionally, oxidized β-cyclodextrin was introduced into the hydrogel formulation to form dynamic bonds with tyramine functionalities, which enables self-healing behavior and resistance to shear. Feasibility of hydrogel implantation combined with pedicle screws was qualitatively assessed in cadaveric sheep as a model for instrumented spinal surgery. The in-situ crystallization of bupivacaine within the hydrogel matrix provided a moderate burst decrease and sustained release that exceeded 72 hours in vitro. The use of bupivacaine crystals decreased drug-induced cytotoxicity in vitro compared to bupivacaine HCl. Thus, the presented robust hydrogel formulation provides promising properties to enable the stationary release of non-opioid analgesics following spinal surgery. STATEMENT OF SIGNIFICANCE: Currently, postoperative pain following spinal surgery is mainly treated with opioids. However, the use of opioids is associated with several side effects including addiction. Here we developed robust and cytocompatible gelatin hydrogels, prepared via riboflavin-mediated photocrosslinking, that can withstand orthopedic implantation. The implantability was confirmed in cadaveric instrumented spinal surgery. Further, hydrogels were loaded with bupivacaine crystals to provide sustained release beyond 72 hours in vitro. The use of crystallized bupivacaine decreased cytotoxicity compared to bupivacaine HCl. The present formulation can aid in enabling opioid-free analgesia following instrumented spinal surgery.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Anesthesia and Pain Management · Pain Management and Opioid Use · Spine and Intervertebral Disc Pathology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (68)
Show source-provided references
1. Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures10.1097/ALN.0b013e31828866b3 ↗
2. PAIN-OUT-Spain consortium, postoperative pain management in Spanish hospitals: a cohort study using the PAIN-OUT registry10.1016/j.jpain.2017.05.006 ↗
3. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes10.1002/phar.1223 ↗
4. Clinical and economic burden of opioid use for postsurgical pain: focus on ventilatory impairment and ileus10.1002/j.1875-9114.2012.01178.x ↗
5. Psychoactive substance use prior to the development of iatrogenic opioid abuse: a descriptive analysis of treatment-seeking opioid abusers10.1016/j.addbeh.2016.08.024 ↗
6. The surge of opioid use, addiction, and overdoses: responsibility and response of the US Health care system10.1001/jamapsychiatry.2017.0163 ↗
7. Consequences of inadequate postoperative pain relief and chronic persistent postoperative pain10.1016/j.atc.2004.11.013 ↗
8. Poorly controlled postoperative pain: prevalence, consequences, and prevention10.2147/JPR.S144066 ↗
9. Review of local anaesthetic agents
10. Drug delivery systems for prolonged duration local anesthesia10.1016/j.mattod.2016.11.019 ↗
11. Synthesis of lidocaine-loaded PLGA microparticles by flow focusing10.1016/j.ijpharm.2008.02.012 ↗
12. Inhibition by local bupivacaine-releasing microspheres of acute postoperative pain from hairy skin incision10.1213/ANE.0b013e3182a00851 ↗
13. The safety of liposome bupivacaine, a novel local analgesic formulation
14. Toxicity of bupivacaine encapsulated into liposomes and injected intravenously10.1213/00000539-199303000-00018 ↗
15. HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phase 3 EPOCH 2 study10.1007/s10029-019-02023-6 ↗
16. A randomized, multicenter, pilot study comparing the efficacy and safety of a bupivacaine-collagen implant (XaraColl(®)) with the ON-Q PainBuster(®) Post-op Pain Relief System following open gynecological surgery10.2147/JPR.S37310 ↗
17. Multivesicular liposomal bupivacaine at the sciatic nerve10.1016/j.biomaterials.2014.02.015 ↗
18. A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy10.1007/s12325-011-0052-y ↗
19. Use of liposomal bupivacaine in the postoperative management of posterior spinal decompression10.3171/2015.11.SPINE15957 ↗
20. Local myotoxicity from sustained release of bupivacaine from microparticles10.1097/ALN.0b013e31816c8a48 ↗
21. Biocompatibility of lipid-protein-sugar particles containing bupivacaine in the epineurium10.1002/jbm.1261 ↗
22. Hydrogels in drug delivery: progress and challenges10.1016/j.polymer.2008.01.027 ↗
23. Pain management via local anesthetics and responsive hydrogels10.4155/tde.14.95 ↗
24. Oxidized cyclodextrin-functionalized injectable gelatin hydrogels as a new platform for tissue-adhesive hydrophobic drug delivery10.1039/C7RA04137C ↗
25. Drug delivery from gelatin-based systems10.1517/17425247.2015.1037272 ↗
26. Gelatin as a delivery vehicle for the controlled release of bioactive molecules10.1016/j.jconrel.2005.09.023 ↗
27. Gelatin methacryloyl and its hydrogels with an exceptional degree of controllability and batch-to-batch consistency
28. Rapid and cytocompatible cell-laden silk hydrogel formation via riboflavin-mediated crosslinking10.1039/D0TB01731K ↗
29. Exploration of inclusion complexes of neurotransmitters with β-cyclodextrin by physicochemical techniques10.1016/j.cplett.2016.05.031 ↗
30. Oxidized cyclodextrin-functionalized injectable gelatin hydrogels as a new platform for tissue-adhesive hydrophobic drug delivery10.1039/C7RA04137C ↗
31. Mechanically resilient, injectable, and bioadhesive supramolecular gelatin hydrogels crosslinked by weak host-guest interactions assist cell infiltration and in situ tissue regeneration10.1016/j.biomaterials.2016.05.043 ↗
32. A comprehensive review on cyclodextrin-based carriers for delivery of chemotherapeutic cytotoxic anticancer drugs10.1155/2015/198268 ↗
33. Cyclodextrin-based pharmaceutics: past, present and future10.1038/nrd1576 ↗
34. Local neurotoxicity and myotoxicity evaluation of cyclodextrin complexes of bupivacaine and ropivacaine10.1213/ANE.0b013e318266f3d9 ↗
35. Biocompatibility of chemically cross-linked gelatin hydrogels for ophthalmic use10.1007/s10856-010-4035-3 ↗
36. 2020 · 3
37. Molecular interactions and the benesi-hildebrand equation10.1021/ja01020a004 ↗
38. Study to explore inclusion complexes of Α- and Β-cyclodextrin molecules with 3-octyl-1-methylimidazolium bromide with the manifestation of hydrophobic and hydrophilic interactions10.1016/j.cplett.2018.07.019 ↗
39. Glycosaminoglycan-based hydrogels capture inflammatory chemokines and rescue defective wound healing in mice10.1126/scitranslmed.aai9044 ↗
40. Enzymatically crosslinked silk and silk-gelatin hydrogels with tunable gelation kinetics, mechanical properties and bioactivity for cell culture and encapsulation10.1016/j.biomaterials.2019.119720 ↗
41. 2021
42. Development and validation of analytical method for simultaneous estimation of bupivacaine and meloxicam in human plasma using UPLC-MS/MS10.5530/phm.2018.1.2 ↗
43. Collagenase in wound healing: Effect of wound age and type10.1111/1523-1747.ep12614202 ↗
44. Gelatinase activity during wound healing
45. Photocrosslinkable gelatin hydrogel for epidermal tissue engineering10.1002/adhm.201500005 ↗
46. pH Optimization of amidation via carbodiimides10.1021/ie401724m ↗
47. An improved method for conjugating monoclonal antibodies with n -hydroxysulfosuccinimidyl DOTA10.1021/bc0000886 ↗
48. Medical applications of rose bengal- and riboflavin-photosensitized protein crosslinking10.1111/php.13126 ↗
49. Analytical techniques for characterization of cyclodextrin complexes in aqueous solution: a review10.1016/j.jpba.2014.02.022 ↗
50. Study of the interaction between S(−) bupivacaine and 2-hydroxypropyl-β-cyclodextrin10.1016/j.ijpharm.2006.09.054 ↗
51. Phase solubility, 1H NMR and molecular modelling studies of bupivacaine hydrochloride complexation with different cyclodextrin derivates10.1016/j.cplett.2010.10.046 ↗
52. Hydrogels in pharmaceutical formulations10.1016/S0939-6411(00)00090-4 ↗
53. Effect of swelling ratio of injectable hydrogel composites on chondrogenic differentiation of encapsulated rabbit marrow mesenchymal stem cells in vitro10.1021/bm801197m ↗
54. Synthesis, properties, and biomedical applications of gelatin methacryloyl (GelMA) hydrogels10.1016/j.biomaterials.2015.08.045 ↗
55. The influence of the stiffness of GelMA substrate on the outgrowth of PC12 cells
56. The in vivo degradation, absorption and excretion of PCL-based implant10.1016/j.biomaterials.2005.09.019 ↗
57. Differential degradation rates in vivo and in vitro of biocompatible poly(lactic acid) and poly(glycolic acid) homo- and co-polymers for a polymeric drug-delivery microchip10.1163/1568562041959991 ↗
58. Sigma Aldrich, Collagenase from C. histolyticum Product Information, (n.d.) 1–3. https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Datasheet/3/c9891dat.pdf (accessed December 18, 2020).
59. Increasing mechanical strength of gelatin hydrogels by divalent metal ion removal10.1038/srep04706 ↗
60. Enzymatic action as switch of bulk to surface degradation of clicked gelatin-based networks10.1002/pat.3962 ↗
61. Size and shape of protein molecules at the nanometer level determined by sedimentation, gel filtration, and electron microscopy10.1007/s12575-009-9008-x ↗
62. Achieving high drug loading and sustained release of hydrophobic drugs in hydrogels through in situ crystallization10.1002/mabi.201600299 ↗
63. Determination of local tissue concentrations of bupivacaine released from biodegradable microspheres and the effect of vasoactive compounds on bupivacaine tissue clearance studied by microdialysis sampling10.1023/A:1020725917197 ↗
64. Regional distribution of 11C-labeled lidocaine, bupivacaine, and ropivacaine in the heart, lungs, and skeletal muscle of pigs studied with positron emission tomography10.1002/(SICI)1099-081X(199703)18:2<151::AID-BDD8>3.0.CO;2-H ↗
65. Mesenchymal stem cells10.1002/jor.1100090504 ↗
66. Riboflavin depletion impairs cell proliferation in adult human duodenum: Identification of potential effectors10.1007/s10620-010-1374-3 ↗
67. Riboflavin deficiency causes protein and DNA damage in HepG2 cells, triggering arrest in G1 phase of the cell cycle10.1016/j.jnutbio.2005.05.004 ↗
68. Comparison of in vitro and in vivo Toxicity of Bupivacaine in Musculoskeletal applications10.3389/fpain.2021.723883 ↗